Summary
Pfizer Inc. announced on June 3, 2013, the successful completion of a significant public offering of notes, raising an aggregate principal amount of $4 billion. This offering diversifies the company's debt structure with tranches ranging from short-term floating rate notes to longer-term fixed-rate notes maturing up to 2043. The notes were issued under Pfizer's existing shelf registration statement, indicating a well-established framework for accessing capital markets. The transaction involved key financial institutions as underwriters, with detailed agreements and indentures filed as exhibits to this Form 8-K, providing transparency on the terms and conditions of the debt issuance.
Key Highlights
- 1Pfizer completed a $4 billion public offering of notes on June 3, 2013.
- 2The offering included various maturities, such as 2017, 2018, 2023, and 2043.
- 3The notes offered have coupon rates ranging from 0.900% to 4.300% for fixed-rate notes, and a floating rate option.
- 4The issuance was conducted under Pfizer's existing shelf registration statement filed in May 2012.
- 5Underwriting and pricing agreements were executed on May 28, 2013, with prominent financial institutions.
- 6The notes were issued pursuant to a supplemented indenture dated June 3, 2013.
- 7Associated legal opinions and consents regarding the validity of the notes are filed as exhibits.
Frequently Asked Questions
This Form 8-K was filed to report on the completion of Pfizer Inc.'s public offering of $4 billion aggregate principal amount of notes.
Pfizer raised a total of $4,000,000,000 (four billion dollars) in aggregate principal amount through this public offering of notes.
The offering included $750 million of 0.900% Notes due 2017, $1 billion of 1.500% Notes due 2018, $500 million of Floating Rate Notes due 2018, $1 billion of 3.000% Notes due 2023, and $750 million of 4.300% Notes due 2043.
The notes were issued under Pfizer's shelf registration statement on Form S-3 (Registration No. 333-181321) filed with the SEC on May 10, 2012.